Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), advancing in two late-stage, registrational clinical trials in two indications Phase 3 sunRIZE study on track;… Read More>>
